Early clinical testing of cognition enhancers: prediction of efficacy.
The major problem in predicting clinical efficacy from animal experimental results and phase I data is the lack of resemblance between the models used and the clinical condition. This problem is complicated by the diversity of the potential mechanisms of action of new compounds. A further question is whether Phase I studies should be used as predictors of clinical efficacy at all. Should they be used simply for determining pharmacologically active dose ranges and tolerance? If used as predictors should drug development stop if negative results are obtained? These questions were not resolved. It was nonetheless suggested that some human models (e.g. scopolamine-induced amnesia, hypoxia-induced performance deficits) were indeed potential predictors of clinical response and, in addition, were analogous to similar models in animals. On the other hand characterisation of quantified EEG (QEEG) profiles remained controversial.
Hall
S T
ST
Glaxo Group Research, Clinical Pharmacology, Greenford, England.
Puech
A
A
Schaffler
K
K
Wesnes
K
K
Gamzu
E R
ER
D000544:Alzheimer Disease / Q000188:drug therapy / Q000523:psychology; D000818:Animals; D003071:Cognition / Q000187:drug effects*; D003072:Cognition Disorders / Q000188:drug therapy* / Q000523:psychology; D006801:Humans; D011597:Psychomotor Performance / Q000187:drug effects